跳至主要内容
临床试验/JPRN-jRCT2071210072
JPRN-jRCT2071210072进行中(未招募)2 期

Investigator-initiated phase II trial to evaluate the efficacy and safety of Acotiamide in patients with esophagogastric junction outflow obstruction

Ihara Eikichi0 个研究点目标入组 42 人开始时间: 2021年10月2日最近更新:

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1) Patients over the age of 20 at the time of consent.
  • 2) Patients diagnosed as EGJOO by HRM according to Chicago Classification ver3.0.
  • 3) Patients who have been experiencing sensation of food sticking in chest for at least one month prior to the time of consent, and have a score of 2 (symptomatic and slightly troubled) or higher on at least one evaluation of food sticking symptoms during the previous week of observation.
  • 4) Patients who have undergone esophagogastroduodenoscopy and esophagography, and have been excluded from other organic diseases that may cause symptoms(e.g.reflux esophagitis, eosinophilic esophagitis, gastric ulcer, etc.) .
  • 5) Patients who understand the contents of the clinical trial and have given written consent of their own free will.

排除标准

  • 1) Patients with clinically evident hepatic dysfunction (AST or ALT in the previous observation period is three times or more than the upper limit of the institutional standard range)
  • 2) Patients with severe renal dysfunction or renal insufficiency (creatinine clearance of less than 30 mL/min in the previous observation period)
  • 3) Patients with a history of hypersensitivity to any component of the investigational drug
  • 4) Patients who have taken acotiamide orally in the month prior to obtaining consent
  • 5) Patients with concomitant malignancy. However, patients with completely resected basal cell carcinoma, Stage I spinous cell carcinoma, intraepithelial carcinoma, intramucosal carcinoma, or superficial bladder cancer may be included the study.
  • 6) Patients with frequent irregular dietary habits, such as not eating or binge drinking/eating.
  • 7) Patients with a history of upper gastrointestinal surgery. However, surgeries related to endoscopic treatment including endoscopic polypectomy, endoscopic mucosal resection and endoscopic submucosal dissection are excluded.
  • 8) Patients who have participated in other clinical trials or clinical studies, and used or are using investigational drugs, devices, or products during the 3 months prior to obtaining consent.
  • 9) Patients with serious cardiac or hematological diseases.
  • 10) Patients with serious drug allergies
  • 11) Female patients who are pregnant, lactating, or of childbearing potential
  • 12) Patients who refuse to use appropriate contraceptive methods during the study period.
  • 13) Patients who are judged by the principal investigator or sub-investigator to be inappropriate for the study.

研究者

发起方
Ihara Eikichi

相似试验